The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer

EuroIntervention

Volumn 6, Issue 2, 2010, Pages 233-239

  Garg, Scot ^a   Sarno, Giovanna ^a   Serruys, Patrick W ^a   De Vries, Ton ^b   Buszman, Pawel ^c   Linke, Axel ^d   Ischinger, Thomas ^e   Klauss, Volker ^f   Eberli, Franz ^g   Corti, Roberto ^h   Wijns, William ⁱ   Morice, Marie Claude ^j   Di Mario, Carlo ^k   Van Geuns, Robert Jan ^a   Eerdmans, Pedro ^l   Van Es, Gerrit Anne ^b   Meier, Bernhard ^m   Jüni, Peter ^m,n   Windecker, Stephan ^m  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^e KLINIKUM BOGENHAUSEN   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g Triemli Spital ^*  (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ OLV HOSPITAL   (Belgium)

^j Institut Jacques Cartier Massy   (France)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l Biosensors International Group Ltd   (Switzerland)

^m UNIVERSITY OF BERN   (Switzerland)

ⁿ UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Biodegradable polymer; Biolimus eluting stent; Sirolimus eluting stent

Indexed keywords

BIOLIMUS; BIOPOLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; BIOLIMUS A9; DRUG DERIVATIVE; LACTIC ACID; POLYLACTIC ACID; POLYMER;

ADULT; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROSPECTIVE STUDY; TIME;

ABSORBABLE IMPLANTS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77956164466     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I2A37     Document Type: Article

References (30)

1. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-48. (Pubitemid 47393576)
2. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, the SSG. Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden. N Engl J Med. 2007;356:1009-1019. (Pubitemid 46376801)
3. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-55; discussion 1455.
4. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-814. (Pubitemid 44871464)
5. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR, Jr., Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-7. (Pubitemid 26320276)
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
7. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006;3:731-41. (Pubitemid 46017613)
8. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S. Randomised comparison of Nobori™, biolimus A 9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention. 2007;2:426-434.
9. Chevalier B, Silber S, Park S-J, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice M-C, Carrie D, van Es G-A, Nagai H, Detiege D, Paunovic D, Serruys PW, for the NCI. Randomized Comparison of the Nobori Biolimus A9-Eluting Coronary Stent With the Taxus Liberte Paclitaxel-Eluting Coronary Stent in Patients With Stenosis in Native Coronary Arteries: The NOBORI 1 Trial - Phase 2. Circ Cardiovasc Intervent. 2009;2:188-195.
10. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-73.
11. Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo B-K, Fitzgerald PJ, Mehran R, Lansky AJ. 9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study. J Am Coll Cardiol. 2009;53:1031-9.
12. Grube E. Custom clinical programme. EuroPCR May 19th-22nd 2008; Barcelona. [online] Available www.europcronline.com/fo/lecture/view-slide.php? idCongres=4&id=5514 [Accessed June 18th 2009].
13. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
14. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive metaanalysis of randomized trials and observational studies. Circulation. 2009;119:3198-206.
15. Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, Rogers EW, Breall JA, Lewis DH, Song A, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS, for the AaAPP. Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries. Circ Cardiovasc Intervent. 2009;2:285-293.
16. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80. (Pubitemid 34586912)
17. Linke A, Lenk K, Serruys P, van Es GA, Buszman P, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, di Mario C, Juni P, Schuler G, Windecker S. Impact of diabetes on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer. LEADERS trial substudy. Poster presentation Transcatheter Therapeutics, San Francisco, September 20th 2009.
18. Buszman P. Outcomes with drug-eluting stents in acute coronary syndromes. A substudy from the LEADERS trial. Presentation EuroPCR, Barcelona, 20th May 2009.
19. Garg S. The outcome of bifurcation lesion stenting using a biolimus eluting stent with a biodegradable polymer compared to a sirolimus eluting stent with a durable polymer. Presentation EuroPCR, 20th May 2009. Online www.europcronline.com/fo/lecture/view-slide.php?idCongres=5&id=7856. Accessed July 14th 2009.
20. Wykrzykowska J, Serruys P, Onuma Y, De Vries T, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice MC, Dimario C, van Geuns RJ, Juni P, Windecker S. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer. LEADERS trial substudy. JACC Cardiovasc Interv. 2009;2:861-870.
21. Wykrzykowska JJ, Raber L, de Vries T, Bressers M, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Regar E, Juni P, Windecker S, Serruys PW. Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. EuroIntervention. 2009;5:310-7.
22. Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes Jr DR. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circulation: Cardiovascular Interventions. 2008;1:10.
23. Jeremias A, Baim DS, Ho KK, Chauhan M, Carrozza JP, Jr., Cohen DJ, Popma JJ, Kuntz RE, Cutlip DE. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol. 2004;44:1210-4. (Pubitemid 39208875)
24. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo A. Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate-Eluting Polymer Stent System in Humans. Circulation. 2002;106:2649-2651. (Pubitemid 35364917)
25. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-5. (Pubitemid 38222887)
26. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-81. (Pubitemid 43005183)
27. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-9.
28. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. Eurointervention. 2008;4 Suppl C:C7-10.
29. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R, for the CI. Safety and Efficacy of Biodegradable Polymer-Coated Sirolimus-Eluting Stents in "Real-World" Practice: 18-Month Clinical and 9-Month Angiographic Outcomes. J Am Coll Cardiol Intv. 2009;2:303-309.
30. Chevalier B. Nobori I - Long term results. Two years Phase 1, One year Phase 2. EuroPCR, Barcelona 2008. [Online] Available: www.europcronline.com/fo/ lecture/view-slide.php?idCongres=4&id=4540. Accessed August 1st 2009.